BTK Inhibitor BGB-3111

Known as: BGB-3111, BTK-InhB 
An orally available inhibitor of Bruton tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, BGB-3111 selectively binds… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
01220062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia… (More)
  • table 1
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK… (More)
Is this relevant?
Review
2016
Review
2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class… (More)
  • table 1
  • table 2
Is this relevant?
Review
2016
Review
2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis… (More)
  • figure 1
  • table 1
Is this relevant?
2015
2015
OBJECTIVE To evaluate the clinical significance of basal reproductive hormones and basal inhibin B (INHB) combined with age on… (More)
Is this relevant?
2006
2006
OBJECTIVE To evaluate the predictive value of serum inhibin B (INH B) levels as an indicator of the presence of testicular… (More)
Is this relevant?